RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly USDA-approved NOBIVAC® NXT vaccine platform to include a best in class solution to protect cats against one of the most common feline infectious diseases, feline leukemia virus (FeLV).

新泽西州拉赫韦（商业新闻短讯）--默克动物健康公司（Merck Animal Health）是美国新泽西州拉赫韦市默克公司（NYSE:MRK）的一个部门，在美国和加拿大以外被称为MSD Animal Health，今天宣布扩展美国农业部新批准的NOBIVAC®NXT疫苗平台，以包括一种一流的解决方案，以保护猫免受最常见的猫传染病之一，猫白血病病毒（FeLV）。

The vaccine is expected to be available at veterinary clinics and hospitals nationwide this fall..

预计该疫苗将于今年秋季在全国的兽医诊所和医院上市。。

NOBIVAC NXT FeLV is the first and only feline leukemia virus vaccine built on Merck Animal Health’s RNA-particle technology platform and is designed to deliver optimized protection. The same technology was used for NOBIVAC NXT Rabies that launched in Canada in June 2024 and NOBIVAC NXT Canine Flu H3N2 that launched in the U.S.

NOBIVAC NXT FeLV是第一个也是唯一一个建立在默克动物健康公司RNA颗粒技术平台上的猫白血病病毒疫苗，旨在提供优化的保护。同样的技术也用于2024年6月在加拿大推出的NOBIVAC NXT狂犬病和在美国推出的NOBIVAC NXT犬流感H3N2。

in June 2024..

2024年6月。。

“We are proud to extend our RNA-particle technology with a vaccine that protects against one of the most persistent threats to our feline patients,” said Ian Tarpey, vice president, research and development, Merck Animal Health. “Merck Animal Health and our NOBIVAC brand have a rich history in vaccine innovation, and we’re continuing to prove our dedication to ensuring there are safe and effective treatment options for veterinary professionals with the latest development of NOBIVAC NXT FeLV.”.

默克动物健康公司研发副总裁伊恩·塔佩伊（IanTarpey）表示：“我们很自豪能够用一种疫苗来扩展我们的RNA颗粒技术，这种疫苗可以保护我们的猫科动物免受最持久的威胁之一。”。“默克动物健康公司（Merck Animal Health）和我们的NOBIVAC品牌在疫苗创新方面有着丰富的历史，我们正在继续证明我们的决心，以确保兽医专业人员能够通过NOBIVAC NXT FeLV的最新开发获得安全有效的治疗选择。”。

NOBIVAC NXT FeLV is a nonadjuvanted, low volume 0.5 mL dose vaccine that harnesses the natural ability of the immune system to generate a robust response without compromising comfort or safety. The Nobivac NXT FeLV vaccine is labeled effective against persistent viremia and is indicated for the vaccination of cats 8 weeks of age or older against FeLV.

NOBIVAC NXT FeLV是一种非辅助的低剂量0.5毫升疫苗，它利用免疫系统的自然能力产生强大的反应，而不会影响舒适性或安全性。Nobivac NXT FeLV疫苗被标记为对持续性病毒血症有效，适用于8周龄或以上的猫接种FeLV。

According to the label and recommendations from the American Association of Feline Practitioners (AAFP), the vaccine should be administered in 2 doses, 3- to 4-weeks apart. The product’s proven 2-year duration of immunity (DOI) follows the AAFP’s recommendations for extended duration protection..

根据美国猫科医生协会（AAFP）的标签和建议，疫苗应分2剂，间隔3至4周。该产品经验证的2年免疫期（DOI）遵循AAFP关于延长免疫期保护的建议。。

Feline leukemia virus can spread in a multitude of ways – most often through mutual grooming, fighting behavior, and shared food, water, or litter trays – and poses serious health risks. Kittens or young cats, outdoor cats and cats who are frequently exposed to other cats are all at increased risk for FeLV.

猫白血病病毒可以通过多种方式传播-通常是通过相互梳理，打架行为以及共享食物，水或垃圾托盘-并构成严重的健康风险。小猫或幼猫、户外猫和经常接触其他猫的猫都会增加FeLV的风险。

When a cat is infected with FeLV, initially they often show no symptoms. However, as FeLV persists in the cat, the virus can lead to cancer, severe blood disorders and other infections associated with a compromised immune system. The good news is routine vaccination can help protect from potential illness..

当猫感染FeLV时，最初它们通常没有症状。。好消息是常规疫苗接种可以帮助预防潜在疾病。。

“Nearly 4% of cats in North America alone are affected by this disease, a notable percentage when there have been guidelines for prevention in place for decades, and especially since the virus can lead to life-threatening diseases,” said Meg Conlon, DVM, executive director, veterinary professional services, Merck Animal Health.

默克动物健康公司兽医专业服务执行主任梅格·康隆（MegConlon）表示：“仅在北美地区，就有近4%的猫受到这种疾病的影响，这一比例很高，因为几十年来一直有预防指南，特别是因为这种病毒可能导致危及生命的疾病。”。

That’s why education and awareness of the importance of vaccinating against this disease is so important.”.

这就是为什么教育和意识到接种疫苗对这种疾病的重要性如此重要。”。

For more information on Feline Leukemia Virus and options for protection, visit www.merck-animal-health-usa.com/nobivac/nobivac-nxt-felv.

有关猫白血病病毒和保护选择的更多信息，请访问www.merck-animal-health-usa.com/nobivac/nobivac-nxt-felv。

About Merck Animal Health

关于默克动物健康

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.

在美国和加拿大以外被称为MSD的默克公司，我们的目标是团结一致的：我们利用尖端科学的力量来拯救和改善世界各地的生活。一个多世纪以来，我们一直处于研究的前沿，为世界上最具挑战性的疾病提出了药物、疫苗和创新的健康解决方案。

Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products.

默克动物健康是美国新泽西州拉赫韦市默克公司的一个部门，是默克公司的全球动物健康业务。通过致力于健康动物科学®，默克动物健康为兽医、农民、生产者、宠物主人和政府提供最广泛的兽药、疫苗和健康管理解决方案和服务，以及一套广泛的互联技术，包括识别、可追溯性和监测产品。

Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

默克动物健康公司致力于保护和改善动物及其护理人员的健康、福祉和表现。它广泛投资于动态和全面的研发资源以及现代化的全球供应链。默克动物保健公司（Merck Animal Health）在50多个国家开展业务，其产品在约150个市场上销售。

For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram..

。。

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

美国新泽西州拉赫韦默克公司的前瞻性声明

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties.

美国新泽西州拉赫韦市默克公司（以下简称“公司”）的本新闻稿包括1995年《美国私人证券诉讼改革法案》安全港条款所指的“前瞻性声明”。这些声明基于公司管理层当前的信念和期望，并且存在重大风险和不确定性。

There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements..

对于管道候选人，不能保证候选人将获得必要的监管批准，或者证明他们在商业上取得了成功。如果基础假设不准确或风险或不确定性具体化，实际结果可能与前瞻性声明中规定的结果存在重大差异。。

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions..

风险和不确定性包括但不限于一般行业条件和竞争；一般经济因素，包括利率和货币汇率波动；美国和国际上制药行业法规和医疗保健立法的影响；医疗保健成本控制的全球趋势；竞争对手取得的技术进步、新产品和专利；新产品开发固有的挑战，包括获得监管部门的批准；公司准确预测未来市场状况的能力；制造困难或延误；国际经济金融不稳定和主权风险；依赖公司专利和其他创新产品保护的有效性；以及诉讼风险，包括专利诉讼和/或监管行动。。

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov)..

公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。可能导致结果与前瞻性声明中描述的结果产生重大差异的其他因素可以在公司截至2023年12月31日的10-K表年度报告以及公司向证券交易委员会（SEC）提交的其他文件中找到，这些文件可在SEC的互联网网站（www.SEC.gov）上找到。。